Statera Biopharma Advances Next-Gen Proprietary Compositions Based on STAT-200 Platform
07 Março 2022 - 9:30AM
Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical
company creating next-generation immune therapies that focus on
immune restoration and homeostasis, today announced advancement of
its next-gen research activities that builds upon the immune
modulation activity of STAT-200 on Toll-Like Receptors (TLRs) to
improve drug characteristics and clinical benefit beyond opioid
receptors.
The research is based on the discovery that
STAT-200, which originally was designed to antagonize opioid
receptors, modulates multiple signaling pathways through receptors
known as TLRs. These receptors act as master controllers of
inflammation. Statera’s discovery platform identifies novel
compositions that build upon STAT-200 by modulating multiple
cellular targets, versus one, to restore cellular homeostasis.
These findings have led to the selection of promising new
compositions with the potential to treat a range of
inflammatory-related diseases.
“The platform could not have existed before the
discovery of the effect of STAT-200 on TLRs,” said Stephen Wilson,
PhD, Chief Innovation Officer at Statera. “With this knowledge, we
have an immense opportunity to improve drug characteristics and
clinical benefit because we aren’t limited to optimizations based
on opioid receptors alone.”
The platform rapidly screened billions of
potential compositions, resulting in hundreds of promising targets.
The top ten compositions were highly compelling, and three of them
are currently being synthesized for biologic validation. Statera
partnered with MolSoft, a leader in computational chemistry and
bioinformatics software, to conduct the computational discovery
through its proprietary Rapid Isostere Discovery Engine (RIDE)
technology.
“A paradigm shift is daring, but these initial
findings have proven that Statera’s approach can identify
actionable compositions that would be missed using traditional
constraints,” said Dr. Andrew Orry, MolSoft’s Senior Research
Scientist.
Last year, Statera acquired ImQuest Life
Sciences, Inc., which evaluates biologics and pharmaceuticals in
preclinical development. ImQuest plans to begin functional
validation of key compositions and expects to accumulate datasets
to select the best leads for animal safety/efficacy testing in
multiple indications.
About Statera BiopharmaStatera
Biopharma, Inc. (formerly Cytocom, Inc.) is a clinical-stage
biopharmaceutical company developing novel immunotherapies
targeting autoimmune, neutropenia/anemia, emerging viruses and
cancers based on a proprietary platform designed to rebalance the
body’s immune system and restore homeostasis. Statera has a large
platform of toll-like receptor (TLR) agonists with TLR4 and TLR9
antagonists, and the TLR5 agonists, Entolimod and GP532. TLRs are a
class of protein that plays a key role in the innate immune system.
Statera is developing therapies designed to directly elicit within
patients a robust and durable response of antigen-specific killer
T-cells and antibodies, thereby activating essential immune
defenses against autoimmune, inflammatory, infectious diseases, and
cancers. Statera has clinical or preclinical programs for Crohn’s
disease (STAT-201), hematology (Entolimod), pancreatic cancer
(STAT-401) and COVID-19 (STAT-205) in addition to potential
expansion into fibromyalgia and multiple sclerosis. To learn more
about Statera, please visit www.staterabiopharma.com.
Forward Looking StatementsThis
press release contains forward-looking statements that involve
risks and uncertainties. All statements other than statements of
current or historical fact contained in this press release,
including statements regarding the Company’s expected clinical
development timeline for the Company’s product candidates, future
financial position, business strategy, new products, budgets,
liquidity, cash flows, projected costs, regulatory approvals, the
impact of any laws or regulations applicable to the Company, and
plans and objectives of management for future operations, are
forward-looking statements. The words “anticipate,” “believe,”
“continue,” “should,” “estimate,” “expect,” “intend,” “may,”
“plan,” “project,” “will,” and similar expressions, as they relate
to us, are intended to identify forward-looking statements. We have
based these forward-looking statements on the current expectations
about future events held by management. While we believe these
expectations are reasonable, such forward-looking statements are
inherently subject to risks and uncertainties, many of which are
beyond the Company’s control. The Company’s actual future results
may differ materially from those discussed here for various
reasons. The Company discusses many of these risks under the
heading “Risk Factors” in the proxy statement/prospectus filed with
the SEC on June 10, 2021, as updated by the Company’s other filings
with the SEC.
Given these uncertainties, you should not place
undue reliance on these forward-looking statements. The
forward-looking statements included in this press release are made
only as of the date hereof. We do not undertake any obligation to
update any such statements or to publicly announce the results of
any revisions to any of such statements to reflect future events or
developments.
Contacts:
Statera BiopharmaNichol
OchsnerExecutive V.P. Investor Relations and Corporate
Communications(732) 754-2545nichol.ochsner@staterabiopharma.com
FINN PartnersGlenn Silver
(Media) (973) 818-8198glenn.silver@finnpartners.com
FINN PartnersDavid Carey (IR)(212)
867-1768David.carey@finnpartners.com
Statera BioPharma (NASDAQ:STAB)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Statera BioPharma (NASDAQ:STAB)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024